Evidence map›Paper›PMID 42237038›Full record

ArticleNature cancer2026

Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Jack Y Ghannam, Julian Bryan, Jakob Weiss, Daniel Kovarsky, David Merrell, Conor Messer, Kristy Schlueter-Kuck, Geoffrey G Fell, Mary Jane Lim-Fat, Gilbert Youssef and 20 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors.

Jack Y Ghannam *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0275-9099
Julian Bryan *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jakob Weiss *Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3879-0568
Daniel Kovarsky *Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
David Merrell *Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Conor MesserBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Kristy Schlueter-KuckBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Geoffrey G FellDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Mary Jane Lim-FatDivision of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Gilbert YoussefHarvard Medical School, Boston, MA, USA.
Rifaquat RahmanDepartment of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA.
Lei QinDepartment of Imaging, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA.
Geoffrey S YoungDepartments of Radiology, Mass General Brigham, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8213-865X
J Thomas JanesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0007-0887-8482
McKayla Van OrdenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0008-6831-4707
Kathleen L PfaffCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Andrew GansCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0002-6650-380X
Emma S LinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0005-0560-2849
Raymond Y HuangDepartments of Radiology, Mass General Brigham, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA.
Brian P DanyshBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6839-6337
Laxmi ParidaIBM Research, Yorktown Heights, NY, USA.ORCID http://orcid.org/0000-0002-7872-5074
Shuqiang LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9106-6141
Patrick Y WenCenter for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0774-7700
E Antonio ChioccaCenter for Tumors of the Nervous System, Mass General Brigham Cancer Institute & Department of Neurosurgery, Mass General Brigham, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5183-1670
Donna NeubergDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2566-3145
Keith L LigonBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-7733-600X
Itay TiroshDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
David A ReardonCenter for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6674-0157
Gad GetzHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0936-0753
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. catherine_wu@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-3348-5054

Funding

Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Tracy T Batchelor · 2013 to 2026
$33.5M
Understanding and Overcoming T cell Immunosuppression in GlioblastomaP01CA236749 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI E. Antonio Chiocca · 2020 to 2026
$19.5M
Training Program in Nervous System TumorsK12CA090354 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PLOTKIN, SCOTT R · 2001 to 2025
$16.3M
Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
Genetic evolution of glioblastomas during radiation and temozolomide therapyR01CA188228 · NCI · DANA-FARBER CANCER INST · PI BEROUKHIM, RAMEEN, CHAKRAVARTI, ARNAB · 2015 to 2025
$6.9M
Single cell investigation of co-evolution in cancer cells and host cell immune microenvironmentR50CA251956 · NCI · DANA-FARBER CANCER INST · PI Shuqiang Li · 2020 to 2026
$1.4M
Identifying the Determinants of Immunoediting During Glioblastoma ImmunotherapyF30CA298302 · NCI · HARVARD MEDICAL SCHOOL · PI Jack Ghannam · 2025 to 2026
$85k
EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 101044318U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) F30CA298302U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) K12CA090354U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P01CA236749U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P50CA165962U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA188228U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R50CA251956U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) T32GM007753U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) T32GM144273U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine (NLM) 2020A005651U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine (NLM) 5R01LM012434
6 · The paper itself

Abstract

The determinants of immune checkpoint blockade (ICB) response in glioblastoma (GBM) with wild-type isocitrate dehydrogenase remain poorly understood. Here we profiled 181 ICB-treated GBM cases using bulk DNA sequencing, bulk RNA sequencing and single-nucleus RNA sequencing to investigate the genomic features associated with ICB outcomes. Baseline tumor transcriptional subtype was predictive of overall survival following ICB, with mesenchymal (MES) GBM associated with improved outcomes to ICB but not standard chemoradiation. Non-MES-associated genetic lesions, including those in PDGFRA and CDKN2A, were associated with worse survival following ICB but not standard therapy. Tumor mutational burden was not predictive of outcomes. Survival was associated with pre-ICB enrichment for MES-like malignant cells, marked by high human leukocyte antigen class I expression and greater T cell infiltration. Paired tumor analyses linked ICB exposure to outgrowth of subclones harboring lesions associated with non-MES subtypes, supporting MES-to-non-MES transition as a common trajectory of acquired resistance to ICB, distinct from standard chemoradiation.

Indexed as

Biomarkers, TumorBrain NeoplasmsGlioblastomaImmune Checkpoint InhibitorsFemaleGene Expression Regulation, NeoplasticHumansMaleMutationPrognosisBiomarkers, TumorImmune Checkpoint Inhibitors

Identifiers

PMID42237038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.